Literature DB >> 20840675

Prognostic relevance of tumour cell-associated uPAR expression in invasive ductal breast carcinoma.

Matthias Kotzsch1, Katharina Bernt, Katrin Friedrich, Elvira Luther, Sybille Albrecht, Axel Gatzweiler, Viktor Magdolen, Gustavo Baretton, Christian Zietz, Thomas Luther.   

Abstract

AIMS: The urokinase-type plasminogen activator receptor (uPAR) is a key molecule for pericellular proteolysis in tumour cell invasion and metastasis. The aim was to evaluate the prognostic impact of uPAR in invasive breast cancer dependent on which cell types within the tumour express uPAR. METHODS AND
RESULTS: uPAR expression was analysed by immunohistochemistry in 270 tumour tissue specimens of invasive ductal breast carcinomas using tissue microarrays. For evaluation of uPAR immunoexpression we used the epitope-mapped, uPAR domain II-specific monoclonal antibody IID7. High uPAR score values in both tumour cells (uPAR-Tc) and stromal cells were significantly related to high tumour grade (G3), and inversely correlated with oestrogen receptor status. On multivariate analysis, high uPAR-Tc values contributed independent prognostic information for disease-free survival (hazard ratio 1.93, P = 0.007) when adjusted for prognostically relevant clinicopathological parameters, whereas uPAR expression in stromal cells was not related to prognosis. In addition, elevated uPAR-Tc values were found to be prognostic indicators in clinically relevant subgroups of patients with invasive breast cancer.
CONCLUSIONS: In invasive breast cancer uPAR expression in invasive carcinoma cells, but not in stromal cells, has a significant impact on patients' prognosis, and contributes to a more aggressive tumour phenotype.
© 2010 Blackwell Publishing Limited.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20840675     DOI: 10.1111/j.1365-2559.2010.03644.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  11 in total

1.  Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance.

Authors:  Sarah A Andres; Angelena B Edwards; James L Wittliff
Journal:  J Clin Lab Anal       Date:  2012-02       Impact factor: 2.352

2.  Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer.

Authors:  Aaron M LeBeau; Sai Duriseti; Stephanie T Murphy; Francois Pepin; Byron Hann; Joe W Gray; Henry F VanBrocklin; Charles S Craik
Journal:  Cancer Res       Date:  2013-02-11       Impact factor: 12.701

3.  A retrospective study of urokinase-type plasminogen activator receptor (uPAR) as a prognostic factor in cancer of the uterine cervix.

Authors:  Toru Sasaki; Hirotaka Nishi; Chie Nagata; Takeshi Nagai; Toshitaka Nagao; Fumitoshi Terauchi; Keiichi Isaka
Journal:  Int J Clin Oncol       Date:  2014-01-30       Impact factor: 3.402

4.  uPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder--Possible Clinical Implications.

Authors:  Line Hammer Dohn; Helle Pappot; Benedikte Richter Iversen; Martin Illemann; Gunilla Høyer-Hansen; Ib Jarle Christensen; Peter Thind; Lisbeth Salling; Hans von der Maase; Ole Didrik Laerum
Journal:  PLoS One       Date:  2015-08-20       Impact factor: 3.240

5.  uPAR-targeted optical imaging contrasts as theranostic agents for tumor margin detection.

Authors:  Lily Yang; Hari Krishna Sajja; Zehong Cao; Weiping Qian; Laura Bender; Adam I Marcus; Malgorzata Lipowska; William C Wood; Y Andrew Wang
Journal:  Theranostics       Date:  2013-12-17       Impact factor: 11.556

6.  Interleukin-like epithelial-to-mesenchymal transition inducer activity is controlled by proteolytic processing and plasminogen-urokinase plasminogen activator receptor system-regulated secretion during breast cancer progression.

Authors:  Agnes Csiszar; Betül Kutay; Silvia Wirth; Ulrike Schmidt; Sabine Macho-Maschler; Martin Schreiber; Memetcan Alacakaptan; Georg F Vogel; Karin Aumayr; Lukas A Huber; Hartmut Beug
Journal:  Breast Cancer Res       Date:  2014-09-09       Impact factor: 6.466

7.  uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: proof-of-concept in orthotopic xenograft model.

Authors:  Anders Christensen; Karina Juhl; Morten Persson; Birgitte Wittenborg Charabi; Jann Mortensen; Katalin Kiss; Giedrius Lelkaitis; Niclas Rubek; Christian von Buchwald; Andreas Kjær
Journal:  Oncotarget       Date:  2017-02-28

8.  Relationships of protein biomarkers of the urokinase plasminogen activator system with expression of their cognate genes in primary breast carcinomas.

Authors:  Seth B Sereff; Michael W Daniels; James L Wittliff
Journal:  J Clin Lab Anal       Date:  2019-07-29       Impact factor: 2.352

9.  Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study.

Authors:  Martin C Boonstra; Floris P R Verbeek; Andrew P Mazar; Hendrica A J M Prevoo; Peter J K Kuppen; Cornelis J H van de Velde; Alexander L Vahrmeijer; Cornelis F M Sier
Journal:  BMC Cancer       Date:  2014-04-17       Impact factor: 4.430

10.  Identification of cell-surface markers for detecting breast cancer cells in ovarian tissue.

Authors:  Inge T A Peters; Carina G J M Hilders; Cornelis F M Sier; Alexander L Vahrmeijer; Vincent T H B M Smit; J Baptist Trimbos; Peter J K Kuppen
Journal:  Arch Gynecol Obstet       Date:  2016-03-05       Impact factor: 2.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.